Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 1 / Phase 2interventionalRules rewrite

Phase 1 / Phase 2: testing Mirdametinib for Well Differentiated Liposarcoma

This study wants to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.

Official registry: https://clinicaltrials.gov/study/NCT06843967 · Memorial Sloan Kettering Cancer Center · enrollment listed as 54

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Mirdametinib, or Palbociclib. The registry lists allocation as randomized. This study wants to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma.

They plan to enroll about 54 people at 7 sites. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma

Interventions: Mirdametinib, Palbociclib

Primary outcome (registry wording): Maximum tolerated dose (Phase I)

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • A diagnosis of unresectable, recurrent, or metastatic DDLPS
  • Measurable disease as defined by RECIST 1.1
  • A diagnosis of unresectable, recurrent (e.g. recurrent retroperitoneal) or metastatic DDLPS
  • Any number of prior lines of therapy
  • Measurable disease and evidence of progression of disease as defined by RECIST 1.1 (including newly diagnosed disease, new disease sites in a patient who was previously NED, or a 20% growth of existing lesions within 6 months of registration)
  • how well you can do daily activities (ECOG score) ≤ 2
  • Adequate organ and marrow function as defined below (ULN indicates institutional upper limit of normal):

Public study contact (from the registry)

Olayode Babatunde, MD

646-888-4363

zzPDL_MED_Sarcoma_Clinical_Trials@mskcc.org

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

7 listed

FAQ about this NCT record

Is NCT06843967 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06843967?

Phase 1 / Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06843967?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary